Clinical Trial Update: Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing Brigimadlin (BI 907828) to doxorubicin in patients with dedifferentiated liposarcoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• brigimadlin (brigimadlin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Liposarcoma, Dedifferentiated | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-07-04